On August 12, 2013, we reported on the oral arguments, here.
Last Thursday — while I was busy with other affairs — Judge Keenan declined to follow Merck’s suggestion. He won’t get involved in mini-trials, at the fact discovery stage — for a wider class of Fosamax claims.
And that all makes good sense — in streamlining, rather than compounding — the litigation proceedings. Here is his opinion (in the form of a five page low res PDF).